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ABSTRACT 
Objective: This study aims to formulate and characterize the transfersomes for percutaneous delivery of peptides and proteins. In particular, this 
study was a preliminary study for the transfersomes formulation of recombinant human epidermal growth factor (rhEGF) for topical delivery. 
Methods: The transfersomes was prepared by thin film hydration method using phosphatidylcholine and sodium deoxycholate as vesicle former. In 
this study, transfersomes formulas were optimized, namely TF1, TF2, TF3, and TF4 with several ratios of phospholipid and surfactant which were 
90:10, 85:15, 80:20, and 75:25, respectively. Afterward, the transfersomes were characterized in terms of particle size distribution, polydispersity 
index, zeta potential, morphology of vesicles, and deformability index. 
Results: The results showed that the best formulation was TF3 with the ratio of 80:20 with a particle size of 118.6±1.33 nm, polydispersity index of 
0.102±0.011, zeta potential of-30.9±0,46 mV, and deformability index of 1.182±0.08. TEM analysis also showed spherical and unilamellar vesicles of 
transfersomes. 
Conclusion: This work demonstrated that the sodium deoxycholate-based transfersomes could be potential to be further formulated with peptide 
and protein for percutaneous delivery. 
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Advances in biotechnology have resulted in many peptides synthesis 
and use of peptides and proteins in the treatment of various 
diseases. Currently, the most frequent route of administration for 
protein and peptide drugs is via parenteral because they are 
unstable if given orally. Transdermal delivery is an attractive option 
for the delivery of peptides and proteins, since it is invasive and 
avoids first-pass degradation in the gastrointestinal tract (GIT) and 
liver [1]. Besides proteins and peptides that are intended for 
systemic delivery, many peptides also have potential therapeutic or 
cosmetic value if they can be locally administered to target sites 
within the skin [2]. This includes epidermal growth factor (EGF) 
which is used for skin healing, such as chronic wounds, burns, 
diabetic ulcers, and also for cosmetic purposes, for example, to 
disguise scars, keloids, and reduce signs of skin aging [3]. In order to 
be effective for systemic action or as cosmeceutical products, the 
applied peptide must reach its target site sufficiently to generate a 
therapeutic response.  
Meanwhile, skin administration is not an easy route because there is 
an effective barrier to skin penetration, called stratum corneum. It 
consists of a “brick and mortar” like structure with 10–15 layers of 
keratinocytes (bricks) in an intercellular lipid matrix (mortar) [4]. 
Ideal characteristics for substances intended for percutaneous 
delivery are a relatively low molecular weight (<500 Da) and 
melting point (<200 °C), moderate lipophilicity (log P 1-3) and 
aqueous solubility (>1 mg/ml) and high pharmacological potency. 
Because of their hydrophilicity and high molecular weight, ranging 
from 300 Da to greater than 1000 kDa, peptides have poor skin 
permeation and ineffective if administered percutaneously despite 
their high potency [1]. 
Several strategies have been developed to overcome the skin barrier 
and facilitate the permeation of peptides and proteins through the 
skin. This includes encapsulation of peptides and proteins in lipid 
vesicular system, such as transfersomes [5, 6]. Transfersomes is an 
ultradeformable vesicle (UDV) which shows a great ability to 
penetrate the skin by squeeze through the pores in the stratum 
corneum that are less than one-tenth the diameter of the 
transfersomes themselves and delivering the drug to the epidermis 
and dermis [7]. The flexibility of transfersomes membrane is 
achieved by mixing suitable surface-active components (surfactants 
and phospholipids) in the proper ratios [8]. 
Sodium deoxycholate is a bile salts-derived anionic surfactant, which 
was employed as a potent penetration enhancer for topically 
administered drugs because of its membrane destabilizing activity 
[9, 10]. Sodium deoxycholate has been used in a transfersomes 
formulation and could successfully carry insulin to penetrate across 
the skin [11]. 
In the present study, the optimization of transfersomes formulas 
using sodium deoxycholate as a surfactant and the characterization 
of the produced transfersomes were carried out. This study was a 
preliminary study for the formulation of recombinant human 
epidermal growth factor (rhEGF) in transfersomes for topical 
delivery. 
Phospholipon 90G was a gift sample from Lipoid GmbH (Kӧln, 
Germany). Sodium deoxycholate and butylated hydroxytoluene was 
purchased from Sigma (Saint Louis, USA) and Sterlitamak 
Petrochemical Plant (Sterlitamak, Rusia) respectively. Potassium 
dihydrogen phosphate and sodium hydroxide were obtained from 
Merck (Darmstadt, Germany). All other solvents and reagents were 
analytical grade. 
Phospholipid is the main component of vesicles forming agent, 
consisting of hydrophilic and hydrophobic groups, which can form a 
lipid bilayer arrangement in an aqueous medium [12]. Phospholipid 
used in this study was Phospholipon 90G, which is 
phosphatidylcholine from soybeans with purity of more than 94%. 
The used phosphatidylcholine is derived from soybeans, since this 
type of phosphatidylcholine does not cause a smell like 
phosphatidylcholine derived from egg yolk. In addition to 
phospholipids, other components of transfersomes are 
surfactants/edge activators that function to increase the elasticity of 
vesicles, so they can deform through narrow gaps [7]. In this 
formulation, sodium deoxycholate (HLB 16) was chosen as an edge 
activator, because it has a high hydrophilic-lipophilic balance (HLB) 
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value that can provide a high degree of encapsulation for hydrophilic 
drugs [13], such as peptides and proteins. Other surfactant with high 
HLB values, such as polysorbate 80 (HLB 15), was not selected as it 
contains ether linkages and unsaturated alkyl chains that have been 
shown to auto-oxidize in aqueous solution to protein-damaging 
peroxides and reactive aldehydes [14]. Moreover, sodium 
deoxycholate has been used in several studies to produce 
transfersomes and showed high entrapment efficiency value as well 
as increased flux of the penetrated drugs into skin [15, 16]. In this 
study, the transfersomes vesicles were formulated with several 
ratios of phospholipid and surfactant as shown at table 1. Butylated 
hydroxytoluene (BHT) was added as an antioxidant, since 
transfersomes tends to experience chemical instability in the lipid 
phase due to oxidative degradation [12]. The pH of the aqueous 
medium was arranged with pH 7.2 phosphate buffer solution to 
maintain the stability of protein and peptides. 
 
Table 1: Formulation of the transfersomes 
Material Concentration (%) 
TF1 (90:10) TF2 (85:15) TF3 (80:20) TF4 (75:25) 
Phospholipon 90G 4.5 4.25 4 3.75 
Sodium deoxycholate 0.5 0.75 1 1.25 
Butylated hydroxytoluene 0.5 0.5 0.5 0.5 
pH 7.2 phosphate buffer ad 100 ad 100 ad 100 ad 100 
 
The transfersomes was prepared by thin layer hydration method 
followed by extrusion. The thin layer hydration method was applied 
as it is quite simple and easy to conduct on a laboratory scale [17]. 
Firstly, the phospholipid, surfactant, and antioxidant were dissolved 
in ethanol and put in a round bottom flask. The solution was 
subsequently evaporated using a rotary vacuum evaporator (Buchi 
R-100, Switzerland) at 40 °C with the speed of 150 rpm under 
vacuum condition. After the thin layer was formed, it was streamed 
with nitrogen gas and stored in the refrigerator overnight to allow 
complete evaporation of the solvent. Hydration of dry lipid film was 
accomplished by adding pH 7.2 phosphate buffer solution at 37 °C 
with the speed of 50–250 rpm for 45 min. In the process of 
hydration, the temperature used greatly affects the stability of 
phospholipids and also the later active ingredient. If the temperature 
is too high it will disrupt the stability of the phospholipid and cause 
a decrease in transfersomes’ encapsulation efficiency [16]. Peptides 
and proteins are also well known for their thermal instability. After 
hydration, phospholipids form a lipid bilayer vesicles of varying size 
and lamellarity (multilamellar vesicles/MLV) [17, 18]. The resulting 
MLV transfersomes appeared as a milky white suspension.  
In the end, the resulting transfersomes suspension was extruded 
through a polycarbonate membrane (200 nm). Extrusion is the most 
often applied method to convert MLVs to small unilamellar vesicles 
(SUVs) of less than 200 nm or large unilamellar vesicles (LUV) of 
200-1000 nm [17]. The extrusion method also has the advantage of 
being able to produce the resulting mean vesicle size and fairly 
reproducible size distribution from batch-to-batch [19]. In this 
method, the MLV suspension is passed several times through a 
polycarbonate membrane with uniform pores. The average vesicle 
size obtained through extrusion decreases with the addition of 
trans-membrane pressure and the number of extrusion cycles [18]. 
In this study, the transfersomes suspension was extruded through 
200 nm polycarbonate membranes (Avanti Polar Lipids Inc., USA) 
for 11 cycles. After extrusion, the color of the transfersomes 
suspension changed to be more transparent than before. It showed 
that increasing the surfactant concentration resulted more 
transparent transfersomes suspension. The appearance that became 
more transparent indicates that the particle size reduction has 
occurred. In general, the smaller the particle size, the turbidity of the 
colloidal system will decrease. After all the processes were complete, 
the transfersomes suspension was stored in a refrigerator and then 
characterized.  
Particle size analysis and the polydispersity index of the 
transfersomes were measured by dynamic light scattering using a 
Zetasizer Nano ZS90 (Malvern, UK) instrument [20]. The particle 
size distribution of all transfersomes is shown at fig. 1 and the 
measurements of particle size as well as the polydispersity index 
(PDI) of the transfersomes are given in table 2. 
  
 
Fig. 1: Particle size distribution of the transfersomes 
 
Table 2: Particle size distribution and polydispersity index of the thin-film 
Parameter TF1 TF2 TF3 TF4 
Zaverage 156.4 (nm) ± 0.85 138.4 ± 0.55 118.6 ± 1.33 86.8 ± 0.14 
DV-average 200.4 (nm) ± 0.76 167.4 ± 5.86 132.4 ± 4.24 81.3 ± 0.57 
DV-10 99.2  (nm) ± 3.26 86.1 ± 2.98 68.6 ± 2.05 50.9 ± 2.30 
DV-50 193.3  (nm) ± 0.58 158.0 ± 5.20 118.7 ± 2.89 74.9 ± 1.55 
DV-90 314.0  (nm) ± 3.46 267.3 ± 16.50 219.3 ± 12.66 122.3 ± 3.06 
Polydispersity index  0.130 ± 0.011 0.115 ± 0.008 0.102 ± 0.011 0.073 ± 0.018 
All values were represented as mean±SD (n=3) 
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All the formulation had a particle size less than 200 nm, according to 
the pore size of the polycarbonate membrane used in the extrusion 
step. The concentration of phospholipid and surfactant used seems 
to be one of the most dominant parameters influencing the particle 
size. Surfactant concentration gives an inverse relationship with the 
particle size [21]. The results showed that the smallest particle size 
was owned by the formulation with the highest surfactant 
concentration (TF4<TF3<TF2<TF1). Furthermore, the reduction in 
polydispersity was noticed, and this might be attributed to the 
reduction of interfacial tension, ensuring a good emulsification 
process [21]. All formulations had a PDI value of less than 0.2, 
indicating monodisperse particle size distribution. The extrusion 
method and the number of cycles that have been used are sufficient 
to make the transfersomes had a narrow particle size distribution. 
In addition to particle size distribution and polydispersity index, the 
measurement of zeta potential was also conducted using a Zetasizer 
Nano ZS90 (Malvern, UK) instrument [20]. Zeta potential is a 
measure of the magnitude of the electrostatic or charges repulsion 
or attraction between particles in a liquid suspension. Zeta potential 
is a fundamental parameter to describe the stability of a dispersion 
system as the measurement provides detailed insight into the causes 
of dispersion, aggregation or flocculation. A sample with a value of 
zeta potential more positive than+30 mV or more negative than-30 
mV can be said as stable [22]. The zeta potential values are shown in 
table 3, and it revealed that the most stable formulations were TF1 
and TF2, followed by TF3. The net negative charge observed was due 
to the lipid and surfactant composition in the formulation. 
Phosphatidylcholine is a zwitterionic compound with an isoelectric 
point between 6 and 7. During the process of formulation, pH 7.2 
phosphate buffer solution was used as the hydrating medium, where 
the pH was a little bit higher than the isoelectric point of 
phosphatidylcholine, causing phosphatidylcholine carried a negative 
charge [23, 24]. Moreover, sodium deoxycholate used is an anionic 
surfactant, which also contributed to the net negative charge of the 
formulation [13]. 
 
Table 3: Zeta potential of the transfersomes formulation 
Formulation Zeta potential (mV) 
TF1 -38.2 ± 1.10 
TF2 -38.4 ± 1.53 
TF3 -30.9 ± 0.46 
TF4 -29.4 ± 0.66 
All values were represented as mean±SD (n=3) 
 
 
Fig. 2: TEM micrograph of the transfersomes, (A) TF1, 97,000x magnification, (B) TF3, 71,000x magnification 
 
Morphology of vesicles was observed using a transmission electron 
microscope (TEM) (Microscope Tecnai 200 kV D2360 SuperTwin, 
Thermo Fisher Scientific, USA) with an accelerating voltage of 80 kV. 
An aliquot (5 μl) of the transfersomes suspension was placed on a 
carbon-coated grid. Excess solution was carefully removed using 
filter paper. Transmission electron micrograph of TF1 and TF3 
transfersomes are displayed at fig. 2; they show spherical and oval 
vesicles. When a thin film of lipid gets hydrated, it tends to form an 
enclosed vesicular structure with shape ranges from spherical to 
oval in order to attain thermodynamic stabilization by reducing the 
total free energy of the system. No disruption of vesicular structure 
confirmed vesicle integrity, even after application of various 
mechanical stresses such as extrusion [25]. Fig. 2 also shows that the 
vesicle has a unilamellar structure with a particle size of less than 
200 nm, which means the extrusion process had successfully 
reduced the particle size and lamellarity of transfersomes. 
Deformability index is a unique parameter in transfersomes 
preparation that distinguishes transfersomes from other vesicular 
systems. Deformability index was used to examine the flexibility of 
transfersomes. Vesicles with better membrane deformability could 
penetrate the lipid membrane through the hydrophilic pathways or 
pores between the cells without losing their vesicle integrity. This 
will be possible with incorporating surfactants which destabilizes 
the lipid bilayer and increases its fluidity and elasticity. The 
transfersomes vesicles could penetrate pores that are smaller than 
their own diameter because of their ultra-flexible vesicle 
membranes [26]. 
Deformability index was measured by extruding 1 ml of 
transfersomes suspension through a polycarbonate membrane with 
a pore size of 100 nm in a mini-extruder set (Avanti Polar Lipids Inc., 
USA). The extruded suspension volume in 5 min was recorded and 
the particle size was then determined with dynamic light scattering 
method. Deformability index can be calculated using the following 
equation: D= J(rv/rp)^2 
where J is the amount of transfersomes suspension that passed 
through the membrane in 5 min (mL), rv is the particle size of the 
transfersomes that passed through the membrane (nm), and rp is 
membrane pore size (nm) [27]. 
All the transfersomes suspension in the formulations were 
deformable, since they can pass through the membrane, and the 
highest deformability index owned by TF1 as shown at table 4. 
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However, these results did not show any significant value, because 
of the membrane pore size used does not vary much with particle 
sizes in the tested suspension. All the formulation experienced a 
reduction in particle size after extrusion in deformability test. 
Nonetheless, TF3 gave the smallest reduction in particle size after 
extrusion. TF4 measurement was considered invalid because the 
pore size of the membrane used in deformability test was larger 
than its particle size. 
 
Table 4: Deformability index of the transfersomes formulation 
Formulation Volume of extruded transfersomes (ml) Particle size after extrusion (nm) Deformability index 
TF1 1.0 131.1 ± 0.62 1.719 ± 0.02 
TF2 1.0 118.1 ± 1.84 1.396 ± 0.04 
TF3 1.0 108.7 ± 3.63 1.182 ± 0.08 
TF4 1.0 83.5 ± 0.60 0.698 ± 0.01 
All values were represented as mean±SD (n=3) 
 
Based on the transfersomes characterizations, the selected 
transfersomes formulation might be determined for further formulation 
with an active ingredient of rhEGF or other suitable peptides and 
proteins. The selected formula was the transfersomes with a spherical 
shape and unilamellar vesicle, particle size less than 200 nm, 
polydispersity index close to 0, and zeta potential more than ± 30 mV. 
Hence, it was indicated that the best transfersomes formulation is TF3 
with a ratio of phosphatidylcholine and sodium deoxycholate of 80:20, 
which had a spherical shape and unilamellar vesicle with a particle size 
of 118.6±1.33 nm, polydispersity index of 0.102±0.011, zeta potential of-
30.9±0.46, and the best elasticity and deformability properties. It is a 
potential transfersomes formula for further formulation with an active 
ingredient of rhEGF or other suitable peptides and proteins. 
ACKNOWLEDGMENT 
The authors gratefully acknowledge the PTUPT research grant 
support from the ministry of research, technology, and higher 
education, Republic of Indonesia. 
AUTHORS CONTRIBUTIONS 
All the authors have contributed equally 
CONFLICT OF INTERESTS 
The authors have no conflict of interest 
REFERENCES 
1. Benson HAE, Namjoshi S. Proteins and peptides: strategies for 
delivery to and across the skin. J Pharm Sci 2008;97:3591–610.  
2. Namjoshi S, Caccetta R, Benson HAE. Skin peptides: biological 
activity and therapeutic opportunities. J Pharm Sci 
2008;97:2524–42.  
3. Caussa JE, Vila EH. Epidermal growth factor, innovation and 
safety. Med Clin 2015;145:305–12.  
4. Bouwstra JA, Honeywell Nguyen PL, Gooris GS, Ponec M. 
Structure of the skin barrier and its modulation by vesicular 
formulations. Prog Lipid Res 2003;42:1–36. 
5. Badenhorst T, Svirckis D, Wu Z. Pharmaceutical strategies for the 
topical dermal delivery of peptides/proteins for cosmetic and 
therapeutic applications. Austin J Pharmacol Ther 2014;2:1–10. 
6. Chaulagain B, Jain A, Tiwari A, Verma A, Jain SK. Passive 
delivery of protein drugs through the transdermal route. Artif 
Cells Nanomed Biotechnol 2018;46 Suppl1:472–87.  
7. Ascenso A, Raposo S, Catia B, Cardoso P, Mendes T, Praca FG, et 
al. Development, characterization, and skin delivery studies of 
related ultradeformable vesicles: transfersomes, ethosomes, 
and transethosomes. Int J Nanomed 2015;10:5837–51. 
8. Prajapati ST, Patel CG, Patel CN. Transfersomes: a vesicular 
carrier system for transdermal drug delivery. Asian J Biochem 
Pharm Res 2011;1:507–24. 
9. Holm R, Müllertz A, Mu H. Bile salts and their importance for 
drug absorption. Int J Pharm 2013;453:44–5.  
10. Aburahma MH. Bile salts-containing vesicles: promising 
pharmaceutical carriers for oral delivery of poorly water-
soluble drugs and peptide/protein-based therapeutics or 
vaccines. Drug Delivery 2016;23:1847–67.  
11. Malakar J, Oomen S, Nayak AK. Formulation, optimization and 
evaluation of transferosomal gel for transdermal insulin 
delivery. Saudi Pharm J 2012;20:355–63.  
12. Pawar A, Jadhav KR, Chaudhari LH. Transfersome: a novel 
technique which improves transdermal permeability. Asian J 
Pharm 2016;10:425–36. 
13. Bnyan R, Khan I, Ehtezazi T, Saleem I, Gordon S, Francis ON, et 
al. Surfactant effects on lipid-based vesicles properties. J Pharm 
Sci 2018;107:1237–46.  
14. Maggio ET. Polysorbates, peroxides, protein aggregation, and 
immunogenicity–a growing concern. J Excipients Food Chem 
2012;3:45–53. 
15. Abdallah MA. Transfersomes as a transdermal drug delivery 
system for enhancement the antifungal activity of nystatin. Int J 
Pharm Pharm Sci 2013;5:560-7. 
16. Shaji J, Lal M. Praparation, optimization, and evaluation of 
transfersomal formulation for enhanced transdermal delivery 
of a COX-2 inhibitor. Int J Pharm Pharm Sci 2014;6:467–77. 
17. Grimaldi N, Andrade F, Segovia N, Ferrer Tasies L, Sala S, 
Veciana J, et al. Lipid-based nanovesicles for nanomedicines. 
Chem Soc Rev 2016;45:6520–45. 
18. Patil YP, Jadhav S. Novel methods for liposome preparation. 
Chem Phys Lipids 2014;177:8–18.  
19. Lapinski MM, Castro-forero A, Greiner AJ, Ofoli RY, Blanchard 
GJ. Comparison of liposomes formed by sonication and 
extrusion: Rotational and translational diffusion of an 
embedded chromophore. Langmuir 2007;23:11677–83. 
20. Awad RS, Abdelwahed W, Bitar Y. Evaluating the impact of 
preparation conditions and formulation on the accelerated 
stability of tretinoin loaded liposomes prepared by the heating 
method. Int J Pharm Pharm Sci 2015;7:171-8. 
21. Singh S, Vardhan H, Kotla NG, Maddiboyina B, Sharma D, 
Webster TJ. The role of surfactants in the formulation of elastic 
liposomal gels containing a synthetic opioid analgesic. Int J 
Nanomed 2016;11:1475–82. 
22. Malvern. Zetasizer nano series user manual. Worcestershire: 
Malvern Instruments Ltd; 2013. 
23. Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T. 
Characterization and in vitro skin permeation of meloxicam-
loaded liposomes versus transfersomes. J Drug Delivery 
2011;2011:418316.  
24. Surini S, Sarah, Djajadisastra J. Formulation and in vitro 
penetration study of transfersomes gel containing gotu kola 
leaves extract (Centella asiatica L. Urban). J Young Pharm 
2018;10:27–31.  
25. Yusuf M, Sharma V, Pathak K. Nanovesicles for transdermal 
delivery of felodipine: development, characterization, and 
pharmacokinetics. Int J Pharm Invest 2014;4:119–30.  
26. Gonzalez Rodriguez ML, Arroyo CM, Cozar Bernal MJ, Gonzalez 
R PL, Leon JM, Calle M, et al. Deformability properties of 
timolol-loaded transfersomes based on the extrusion 
mechanism. Statistical optimization of the process. Drug Dev 
Ind Pharm 2016;42:1683–94. 
27. Anwar E, Utami TD, Ramadon D. Transfersomal gel containing 
green tea (Camelia sinensis L. Kuntze) leaves extract: increasing 
in vitro penetration. Asian J Pharm Clin Res 2017;10:294-8. 
 
